Venture Capital and Growth Companies
Supporting VCs and growth companies through their journeys from start-up, through growth phases and to maturity and exit.
We advise growth equity investors from early stage, late stage and growth venture funds through to large, international venture capital firms and institutional investors. We also advise the full spectrum of growth companies from start-ups to some of the largest and fastest growing companies in Europe. Our standards of technical excellence, commercial pragmatism and client-focused service apply to all our clients in this space – however big or small.
We have one of the strongest corporate practices in the world and are one of the top law firms for acquisitions, mergers and investments, leading on many of the major European fundraisings in recent times.
What makes us stand out though is our wider expertise. Our multi-disciplinary team has recognised market-leading expertise in Financial Regulation, Antitrust, Foreign Investment, Incentives, Data Privacy, Blockchain, Cyber, AI and more. We have a complete view of the issues facing both investors and growth companies, enabling us to solve those issues in the right way for the particular client rather than rely on “market practice”.
Key Experience
We advised SoftBank Vision Fund as the lead investor in Revolut’s USD800 million series E fundraising round, valuing Revolut at approximately USD33 billion, making it the most valuable fintech company in the UK at the time.
We have advised Monzo since it was founded in 2015. We most recently supported its Series I fundraising, which was led by CapitalG, Alphabet’s independent growth fund, and valued Monzo at c. £4 billion.
We advised Oxford Nanopore Technologies plc from start-up through to its initial public offering on the Main Market of the London Stock Exchange, described by Bloomberg as “one of London’s best-ever debuts”.
We advised retail investment platform PrimaryBid Limited from start-up through to its latest USD190 million Series C fundraising, led by SoftBank Vision Fund 2.
We advised Oxford Science Enterprises on its £250 million capital raise. OSE is an independent investment company created to found, fund and build transformational businesses via its unique partnership with the University of Oxford.
We advised Immunocore, a clinical-stage T cell receptor biotechnology company, on its USD130 million Series B fundraising.
We advised SideQuest, a community platform that enables discovery of VR content for devices such as Meta Quest 2, on its USD12 million Series A funding round, led by Google Ventures.
We advised Aviva Ventures, as lead investor alongside Munich Re, on a £500 million Series A equity investment in Neos, a company which combines smart home technology with home insurance in the UK.